TY - JOUR
T1 - Absorption, tissue distribution and in vivo stability in rats of a hybrid antisense oligonucleotide following oral administration
AU - Agrawal, Sudhir
AU - Zhang, Xueshu
AU - Lu, Zhihong
AU - Zhao, Hui
AU - Tamburin, Jeffrey M.
AU - Van, Jieming
AU - Cai, Hongying
AU - Diasio, Robert B.
AU - Habus, Ivan
AU - Jiang, Zhiwei
AU - Iyer, Radhakrishnan P.
AU - Yu, Dong
AU - Zhang, Ruiwen
PY - 1995/8/8
Y1 - 1995/8/8
N2 - In vivo stability and oral bioavailability of an oligodeoxynucleotide phosphorothioate containing segments of 2′-O-methyloligoribonucleotide phosphorothioates at both the 3′- and 5′-ends (hybrid oligonucleotide) were studied. A 25-mer 35S-labeled hybrid oligonucleotide was administered to rats by gavage at a dose of 50 mg/kg body weight. HPLC analysis revealed that this hybrid oligonucleotide was stable in the gastrointestinal tract for up to 6 hr following oral administration. Radioactivity associated with the hybrid oligonucleotide was detectable in portal venous plasma, systemic plasma, various tissues, and urine. Intact hybrid oligonucleotide was detected, by HPLC analysis, in portal venous plasma, systemic plasma, and various tissues. The majority of the radioactivity in urine was associated with degradative products with lower molecular weights, but the intact form was also detected. In summary, the hybrid oligonucleotide was absorbed intact through the gastrointestinal tract, indicating the possibility of oral administration of oligonucleotides, a finding that may be important in the development of antisense oligonucleotides as therapeutic agents.
AB - In vivo stability and oral bioavailability of an oligodeoxynucleotide phosphorothioate containing segments of 2′-O-methyloligoribonucleotide phosphorothioates at both the 3′- and 5′-ends (hybrid oligonucleotide) were studied. A 25-mer 35S-labeled hybrid oligonucleotide was administered to rats by gavage at a dose of 50 mg/kg body weight. HPLC analysis revealed that this hybrid oligonucleotide was stable in the gastrointestinal tract for up to 6 hr following oral administration. Radioactivity associated with the hybrid oligonucleotide was detectable in portal venous plasma, systemic plasma, various tissues, and urine. Intact hybrid oligonucleotide was detected, by HPLC analysis, in portal venous plasma, systemic plasma, and various tissues. The majority of the radioactivity in urine was associated with degradative products with lower molecular weights, but the intact form was also detected. In summary, the hybrid oligonucleotide was absorbed intact through the gastrointestinal tract, indicating the possibility of oral administration of oligonucleotides, a finding that may be important in the development of antisense oligonucleotides as therapeutic agents.
KW - HIV
KW - antisense oligonucleotides
KW - oral bioavailability
UR - http://www.scopus.com/inward/record.url?scp=0029100397&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029100397&partnerID=8YFLogxK
U2 - 10.1016/0006-2952(95)00160-2
DO - 10.1016/0006-2952(95)00160-2
M3 - Article
C2 - 7646565
AN - SCOPUS:0029100397
SN - 0006-2952
VL - 50
SP - 571
EP - 576
JO - Biochemical Pharmacology
JF - Biochemical Pharmacology
IS - 4
ER -